{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:16Z","timestamp":1792788616185,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Copenhagen University","id":[{"id":"https:\/\/ror.org\/035b05819","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Completion axillary lymph node dissection (ALND) is no longer routinely recommended for patients with breast cancer and minimal nodal involvement. In 2012, Danish national guidelines were revised to omit ALND for patients with sentinel node (SN) micrometastases (pN1mi) or isolated tumor cells (pN0[i+]). Long-term evidence on axillary recurrence (AR) and overall survival (OS), particularly after mastectomy, remain limited. This nationwide retrospective register-based study evaluated long-term outcomes after omission of ALND.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Clinically node-negative women with pN1mi\/pN0(i+) diagnosed between 2008 and 2021 were identified in the Danish Breast Cancer Group database. Patients treated before 2012 (ALND group) were compared with those treated after guideline revision in 2012 (no-ALND group). Both groups were compared with node-negative patients (pN0) treated after 2012. The primary endpoint was AR, and the secondary endpoint was OS. Survival was analyzed using Kaplan\u2013Meier and multivariable Cox regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 22,253 eligible patients, 5066 had pN1mi\/pN0(i+). The median follow-up period was 6.4\u00a0years. Axillary recurrence occurred for 1.1% of the patients overall and was more frequent among the patients without ALND than among those with ALND (1.5% vs 0.2%;\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Among the pN0 patients without ALND, 0.5% experienced AR. Long-term OS for the pN1mi\/pN0(i+) patients was 81.3% (95% confidence interval, 79.9\u201382.7), with no significant difference after adjustment for prognostic factors (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.6). Mastectomy-specific analysis showed no difference in OS (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.08).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Omission of ALND for patients with minimal SN involvement was associated with a slightly higher rate of AR but no adverse impact on long-term OS. These findings support continued de-escalation of axillary surgery, even for selected patients undergoing mastectomy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20072-x","type":"journal-article","created":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:18:33Z","timestamp":1783343913000},"page":"9080-9088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Axillary Recurrence and Survival After Omission of Axillary Lymph Node Dissection in\u00a0Patients with Breast Cancer and Micrometastases or Isolated Tumor Cells in the Sentinel Node: A Danish National Register Study"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0100-9782","authenticated-orcid":false,"given":"Riazan Heidari Rosenlund","family":"Korsholm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Kroman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tove F.","family":"Tvedskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederikke","family":"Munck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,6]]},"reference":[{"key":"20072_CR1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10549-011-1720-y","volume":"131","author":"TF Tvedskov","year":"2012","unstructured":"Tvedskov TF, Jensen MB, Kroman N, Balslev E. Iatrogenic displacement of tumor cells to the sentinel node after surgical excision in primary breast cancer. Breast Cancer Res Treat. 2012;131:223\u20139.","journal-title":"Breast Cancer Res Treat."},{"key":"20072_CR2","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10549-015-3560-7","volume":"153","author":"TF Tvedskov","year":"2015","unstructured":"Tvedskov TF, Jensen MB, Ejlertsen B, Christiansen P, Balslev E, Kroman N. Prognostic significance of axillary dissection in breast cancer patients with micrometastases or isolated tumor cells in sentinel nodes: a nationwide study. Breast Cancer Res Treat. 2015;153:599\u2013606.","journal-title":"Breast Cancer Res Treat."},{"key":"20072_CR3","first-page":"800","volume":"175","author":"TF Tvedskov","year":"2013","unstructured":"Tvedskov TF. New guidelines for axillary dissection in breast cancer. Ugeskr Laeger. 2013;175:800.","journal-title":"Ugeskr Laeger."},{"key":"20072_CR4","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1080\/02841860802010732","volume":"47","author":"E Friis","year":"2008","unstructured":"Friis E, Galatius H, Garne JP. Organized nation-wide implementation of sentinel lymph node biopsy in Denmark. Acta Oncol. 2008;47:556\u201360.","journal-title":"Acta Oncol."},{"key":"20072_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1080\/0284186X.2017.1404638","volume":"57","author":"MB Jensen","year":"2018","unstructured":"Jensen MB, Laenkholm AV, Offersen BV, et al. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007\u20132016. Acta Oncol. 2018;57:13\u20138.","journal-title":"Acta Oncol."},{"key":"20072_CR6","unstructured":"https:\/\/www.sundk.dk\/media\/l2rp4h4c\/dbcg-a-rsrapport-2024_offentliggjort-version-20250627.pdf."},{"key":"20072_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/0284186X.2017.1401227","volume":"57","author":"C Jessing","year":"2018","unstructured":"Jessing C, Langhans L, Jensen MB, Talman ML, Tvedskov TF, Kroman N. Axillary lymph node dissection in breast cancer patients after sentinel node biopsy<sup\/>. Acta Oncol. 2018;57:166\u20139.","journal-title":"Acta Oncol."},{"key":"20072_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10549-010-1210-7","volume":"125","author":"MJ Pepels","year":"2011","unstructured":"Pepels MJ, Vestjens JH, de Boer M, et al. Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review. Breast Cancer Res Treat. 2011;125:301\u201313.","journal-title":"Breast Cancer Res Treat."},{"issue":"Suppl 1","key":"20072_CR9","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/S0960-9776(19)31124-5","volume":"48","author":"P Veronesi","year":"2019","unstructured":"Veronesi P, Corso G. Standard and controversies in sentinel node in breast cancer patients. Breast. 2019;48(Suppl 1):S53\u20136.","journal-title":"Breast."},{"key":"20072_CR10","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/SLA.0000000000005671","volume":"277","author":"NA Che Bakri","year":"2023","unstructured":"Che Bakri NA, Kwasnicki RM, Khan N, et al. Impact of axillary lymph node dissection and sentinel lymph node biopsy on upper limb morbidity in breast cancer patients: a systematic review and meta-analysis. Ann Surg. 2023;277:572\u201380.","journal-title":"Ann Surg."},{"key":"20072_CR11","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","volume":"19","author":"V Galimberti","year":"2018","unstructured":"Galimberti V, Cole BF, Viale G, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23\u201301): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19:1385\u201393.","journal-title":"Lancet Oncol."},{"key":"20072_CR12","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1470-2045(13)70035-4","volume":"14","author":"V Galimberti","year":"2013","unstructured":"Galimberti V, Cole BF, Zurrida S, et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23\u201301): a phase 3 randomised controlled trial. Lancet Oncol. 2013;14:297\u2013305.","journal-title":"Lancet Oncol."},{"key":"20072_CR13","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1245\/s10434-012-2569-y","volume":"20","author":"M Sol\u00e1","year":"2013","unstructured":"Sol\u00e1 M, Alberro JA, Fraile M, et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048\/13\/2000. Ann Surg Oncol. 2013;20:120\u20137.","journal-title":"Ann Surg Oncol."},{"key":"20072_CR14","doi-asserted-by":"publisher","first-page":"znaf111","DOI":"10.1093\/bjs\/znaf111","volume":"112","author":"Y Andersson","year":"2025","unstructured":"Andersson Y, Bergkvist L, Ryd\u00e9n L, et al. Omitting completion axillary lymph node dissection in breast cancer patients with sentinel lymph node micrometastases undergoing mastectomy: results from the prospective SENOMIC trial. Br J Surg. 2025;112:znaf111.","journal-title":"Br J Surg."},{"key":"20072_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1148\/radiol.2020192534","volume":"295","author":"JM Chang","year":"2020","unstructured":"Chang JM, Leung JWT, Moy L, Ha SM, Moon WK. Axillary nodal evaluation in breast cancer: state of the art. Radiology. 2020;295:500\u201315.","journal-title":"Radiology."},{"key":"20072_CR16","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/bjs\/znab141","volume":"108","author":"Y Andersson","year":"2021","unstructured":"Andersson Y, Bergkvist L, Frisell J, de Boniface J. Omitting completion axillary lymph node dissection after detection of sentinel node micrometastases in breast cancer: first results from the prospective SENOMIC trial. Br J Surg. 2021;108:1105\u201311.","journal-title":"Br J Surg."},{"key":"20072_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10549-018-4820-0","volume":"171","author":"Y Andersson","year":"2018","unstructured":"Andersson Y, Bergkvist L, Frisell J, de Boniface J. Long-term breast cancer survival in relation to the metastatic tumor burden in axillary lymph nodes. Breast Cancer Res Treat. 2018;171:359\u201369.","journal-title":"Breast Cancer Res Treat."},{"key":"20072_CR18","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","volume":"25","author":"AE Giuliano","year":"2018","unstructured":"Giuliano AE, Edge SB, Hortobagyi GN. Eighth edition of the AJCC Cancer Staging Manual: breast cancer. Ann Surg Oncol. 2018;25:1783\u20135.","journal-title":"Ann Surg Oncol."},{"key":"20072_CR19","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2021. Available at: https:\/\/ www.r-project.org\/."},{"key":"20072_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41571-018-0089-9","volume":"16","author":"NF Pond\u00e9","year":"2019","unstructured":"Pond\u00e9 NF, Zardavas D, Piccart M. Progress in adjuvant systemic therapy for breast cancer. Nat Rev Clin Oncol. 2019;16:27\u201344.","journal-title":"Nat Rev Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20072-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20072-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20072-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T17:52:57Z","timestamp":1789667577000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20072-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,6]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20072"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20072-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,6]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}